About Foundation Medicine
Foundation Medicine is a company based in Cambridge (United States) founded in 2010 by Todd Golub, Eric Lander, and Matthew Meyerson was acquired by Roche in January 2015. Foundation Medicine has raised $96.5 million across 4 funding rounds from investors including Roche, Kleiner Perkins and The Gates Notes. Foundation Medicine has completed 2 acquisitions, including Lexent Bio and Saga Diagnostics. Foundation Medicine offers products and services including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme. Foundation Medicine operates in a competitive market with competitors including Guardant Health, MedGenome, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Cambridge, United States
- Founders Todd Golub, Eric Lander, Matthew Meyerson
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Foundation Medicine, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$96.5 M (USD)
in 4 rounds
-
Latest Funding Round
$13.5 M (USD), Series B
Jan 08, 2013
-
Investors
Roche
& 8 more
-
Employee Count
Not available
-
Investments & Acquisitions
Lexent Bio
& 1 more
-
Acquired by
Roche
(Jan 12, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Foundation Medicine
Foundation Medicine offers a comprehensive portfolio of products and services, including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
Test for analyzing tumor genes in advanced cancer patients
Test using cell-free DNA for cancer mutation detection
Test for detecting RNA fusions in cancer samples
Test for genomic profiling in blood cancers
People of Foundation Medicine
Unlock access to complete
Leadership Team
85 people
Software Development Team
52 people
Sales and Marketing
34 people
Senior Team
32 people
Operations Team
27 people
Human Resources and Administration
20 people
Data Analysis and Operations Team
16 people
Legal and Compliance
15 people
Unlock access to complete
Funding Insights of Foundation Medicine
Foundation Medicine has successfully raised a total of $96.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13.5 million completed in January 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Foundation Medicine
Foundation Medicine has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Kleiner Perkins and The Gates Notes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Foundation Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Foundation Medicine
Foundation Medicine has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Lexent Bio and Saga Diagnostics.
Investment portfolio details for Foundation Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bioinformatics and genomic science are provided for cancer diagnosis.
|
Locked | Locked | 2017 | Locked | |
|
Tests for circulating tumor DNA detection and analysis are offered.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Foundation Medicine
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Foundation Medicine
Detailed financials for Foundation Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Foundation Medicine Comparisons
Peer comparison for Foundation Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Foundation Medicine
Foundation Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, MedGenome, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Foundation Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Foundation Medicine
Complete news archive for Foundation Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Foundation Medicine
Foundation Medicine was founded in 2010.
Foundation Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Foundation Medicine is a funded company, having raised a total of $96.5M across 4 funding rounds to date.
Provider of genomics-based diagnostics test for cancer. The companys clinical assays, FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and the liquid biopsy test FoundationACT provide a complete genomic profile of cancers, which oncologists can use to inform their treatment decisions. In addition, all tests provide an estimate of tumor mutational burden that enables oncologists to predict immunotherapy response as well.
Foundation Medicine's top competitors include Guardant Health, Strand Life Sciences and MedGenome.
Foundation Medicine offers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
Foundation Medicine has made 2 acquisitions, including Lexent Bio, and Saga Diagnostics.
Foundation Medicine has 9 investors. Key investors include Roche, Kleiner Perkins, The Gates Notes, Casdin Capital, and Third Rock Ventures.